{"id":"https://openalex.org/W2603592220","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e16512","title":"A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D).","display_name":"A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2603592220","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e16512","mag":"2603592220"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.e16512","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e16512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e16512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068193017","display_name":"David Michael Hyman","orcid":"https://orcid.org/0000-0001-8150-9762","observed_orcids":["https://orcid.org/0000-0001-8150-9762"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Michael Hyman","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072447565","display_name":"Michael W. Sill","orcid":"https://orcid.org/0000-0001-7263-2179","observed_orcids":["https://orcid.org/0000-0001-7263-2179"]},"institutions":[{"id":"https://openalex.org/I117693200","display_name":"Gynecologic Oncology Group","ror":"https://ror.org/04x187e69","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I117693200"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Sill","raw_affiliation_strings":["Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY","institution_ids":["https://openalex.org/I117693200"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049882044","display_name":"Jonathan K. Cho","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039246","display_name":"University of Hawaii Cancer Center","ror":"https://ror.org/00kt3nk56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039246"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan K Cho","raw_affiliation_strings":["University of Hawaii Cancer Center, Honolulu, HI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Hawaii Cancer Center, Honolulu, HI","institution_ids":["https://openalex.org/I4390039246"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032022793","display_name":"Heather A. Lankes","orcid":"https://orcid.org/0000-0001-8814-5033","observed_orcids":["https://orcid.org/0000-0001-8814-5033"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Heather A. Lankes","raw_affiliation_strings":["Gyn Onc Grp, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gyn Onc Grp, Buffalo, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046042179","display_name":"Richard Piekarz","orcid":"https://orcid.org/0000-0002-3591-7893","observed_orcids":["https://orcid.org/0000-0002-3591-7893"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Piekarz","raw_affiliation_strings":["Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032196793","display_name":"Martee Leigh Hensley","orcid":"https://orcid.org/0009-0004-9956-1306","observed_orcids":["https://orcid.org/0009-0004-9956-1306"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martee Leigh Hensley","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"e16512","last_page":"e16512"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10989","display_name":"Uterine Myomas and Treatments","score":0.8413000106811523,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10989","display_name":"Uterine Myomas and Treatments","score":0.8413000106811523,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.12780000269412994,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.009499999694526196,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alisertib","display_name":"alisertib","score":0.906000018119812},{"id":"https://openalex.org/keywords/mln8237","display_name":"MLN8237","score":0.9760000109672546},{"id":"https://openalex.org/keywords/uterine-leiomyosarcoma","display_name":"uterine leiomyosarcoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/aurora-a-kinase-inhibitor","display_name":"Aurora A kinase inhibitor","score":0.9039999842643738},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.734000027179718},{"id":"https://openalex.org/keywords/objective-response","display_name":"objective response","score":0.734000027179718},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.640999972820282},{"id":"https://openalex.org/keywords/mitotic-spindle","display_name":"mitotic spindle","score":0.4230000078678131},{"id":"https://openalex.org/keywords/two-stage-design","display_name":"two-stage design","score":0.6039999723434448},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.5649999976158142},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.5879999995231628}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8475660085678101},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6696056127548218},{"id":"https://openalex.org/C2780435969","wikidata":"https://www.wikidata.org/wiki/Q5625186","display_name":"Gynecologic oncology","level":2,"score":0.6469905376434326},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6366994976997375},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5017406940460205},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.47866329550743103},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.4600086510181427},{"id":"https://openalex.org/C2779425043","wikidata":"https://www.wikidata.org/wiki/Q14905704","display_name":"Aurora A kinase","level":3,"score":0.4577876329421997},{"id":"https://openalex.org/C2780808130","wikidata":"https://www.wikidata.org/wiki/Q24745285","display_name":"Aurora kinase","level":4,"score":0.44693076610565186},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.44218623638153076},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4210747182369232},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2799457609653473},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2603679299354553},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.24703288078308105},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.08645504713058472}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.e16512","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e16512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e16512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2545879467","https://openalex.org/W2332626354","https://openalex.org/W2318348123","https://openalex.org/W2591072078","https://openalex.org/W2270731056","https://openalex.org/W2513820391","https://openalex.org/W2077295631","https://openalex.org/W2460407879","https://openalex.org/W2057466968","https://openalex.org/W4408376280"],"abstract_inverted_index":{"e16512":[0],"Background:":[1],"uLMS":[2,53],"is":[3,37],"an":[4],"aggressive":[5],"disease":[6,281,287],"with":[7,108,183],"limited":[8],"therapeutic":[9],"options.":[10],"Genome":[11],"wide":[12],"transcriptional":[13],"profiling":[14],"of":[15,23,44,65,93,101,106,144,161,187],"uterine":[16],"leiomyosarcoma":[17],"(uLMS)":[18],"has":[19,50],"identified":[20],"frequent":[21],"overexpression":[22],"gene":[24],"products":[25],"involved":[26],"in":[27,54,67,325],"the":[28,45,63,94,99,104,113,142,159],"mitotic":[29],"spindle":[30],"apparatus":[31],"including":[32],"Aurora":[33,46],"A":[34,47,178],"Kinase.":[35],"Alisertib":[36,318],"a":[38,134,145,148,162,184],"highly":[39],"selective":[40],"small":[41],"molecule":[42],"inhibitor":[43],"kinase":[48],"and":[49,86,112,158,193,262,299,308],"activity":[51,64,324],"against":[52],"preclinical":[55],"models.":[56],"We":[57],"conducted":[58],"GOG-0231D":[59],"(NCT01637961)":[60],"to":[61,97,151,156,171,176],"evaluate":[62,98],"alisertib":[66,102],"uLMS.":[68,328],"Methods:":[69],"Eligibility":[70],"criteria":[71],"included":[72],"histologically":[73],"confirmed,":[74],"recurrent":[75],"or":[76,132,154,174,236,247],"persistent":[77],"uLMS,":[78],"age":[79,225],"\u2265":[80],"18,":[81],"1-2":[82],"prior":[83],"cytotoxic":[84,233],"regimens,":[85],"RECIST":[87,129],"measurable":[88],"disease.":[89],"The":[90,124,137,239],"primary":[91],"objective":[92,109,269],"study":[95],"was":[96,181,226,230,279,290],"efficacy":[100],"through":[103],"frequency":[105,114],"patients":[107,189,209,213,284],"tumor":[110,149],"responses":[111,270],"who":[115],"survived":[116],"event-free":[117,165],"for":[118,126,166,190,197,205],"at":[119,167],"least":[120,168],"6":[121,169],"months":[122,170,310],"(EFS6).":[123],"endpoints":[125],"EFS":[127],"were":[128,210,214,249,267,301],"progression,":[130],"death,":[131],"beginning":[133],"subsequent":[135],"therapy.":[136],"null":[138],"hypothesis":[139],"jointly":[140],"specified":[141],"probability":[143,160],"patient":[146,163],"experiencing":[147],"response":[150,278],"less":[152,172],"than":[153,173],"equal":[155,175],"5%":[157],"surviving":[164],"20%.":[177],"two-stage":[179],"design":[180],"used":[182],"target":[185],"accrual":[186],"23":[188,208],"stage":[191,198],"1":[192,232],"47":[194],"pts":[195],"cumulative":[196],"2.":[199],"Confidence":[200],"intervals":[201],"do":[202],"not":[203,320],"correct":[204],"multiplicity.":[206],"Results:":[207],"enrolled.":[211],"2":[212,237],"excluded":[215],"on":[216],"central":[217],"histologic":[218],"review,":[219],"yielding":[220],"21":[221],"eligible":[222],"patients.":[223],"Median":[224,297],"61.":[227],"Prior":[228],"treatment":[229,242],"either":[231],"regimen":[234],"(71.4%)":[235],"(28.6%).":[238],"most":[240],"common":[241],"related":[243],"AEs":[244],"(grade":[245],"3":[246],"worse)":[248],"anemia":[250],"(4),":[251,259],"leukopenia":[252],"(5),":[253],"neutropenia":[254],"(7),":[255],"thrombocytopenia":[256],"(1),":[257,261],"mucositis":[258],"diarrhea":[260],"palmer-planter":[263],"syndrome":[264],"(2).":[265],"There":[266],"no":[268],"(0%;":[271],"90%":[272],"CI":[273,293,304,312],"0":[274,294],"~":[275,295,306,314],"10.4%).":[276,296],"Best":[277],"stable":[280],"(38.1%);":[282],"12":[283],"had":[285],"progressive":[286],"(57.1%).":[288],"EFS6":[289],"0%":[291],"(90%":[292,303,311],"PFS":[298],"OS":[300],"1.7":[302],"1.4":[305],"3.2)":[307],"14.5":[309],"7.6":[313],"NA),":[315],"respectively.":[316],"Conclusions:":[317],"did":[319],"demonstrate":[321],"clinically":[322],"meaningful":[323],"previously":[326],"treated":[327],"Clinical":[329],"trial":[330],"information:":[331],"NCT01637961.":[332]},"counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-04-07T00:00:00"}